Anti-dumping investigation into Penicillin G imports from China
Quick dive
- DGTR initiated an anti-dumping investigation into Penicillin G and its salts imported from China after Lyfius Pharma alleged material retardation to Indian industry.
- Penicillin G is a key starting material and active pharmaceutical ingredient used in medicines for pneumonia, dental infections, diphtheria and meningitis.
- Aurobindo Pharma’s subsidiary restarted domestic beta-lactam antibiotic production after more than three decades under the production-linked incentive scheme.
- The product under consideration covers all forms, grades, strengths and concentrations, and DGTR selected 2025–26 as the investigation period.
- exam_relevance: tests the precise anti-dumping sequence—DGTR prima facie evidence, domestic-industry injury, product scope and PLI-linked API revival—rather than merely asking what antibiotics are.
Full explanation
This explanation is available with full current-affairs access.
Log in to continue